Physician profile
Iraj Rueda
NPI 1639992308
$1,338.04
in general payments reported to CMS, 2019-2025
26 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $161.59 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $140.55 | 2025 | Zynyz, Monjuvi, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $124.07 | 2025 | Iclusig, Alunbrig |
| Tersera Therapeutics LLC | $109.70 | 2025 | Zoladex |
| Genzyme Corporation | $99.81 | 2025 | |
| Genentech USA, INC. | $76.63 | 2025 | Tecentriq Hybreza, Venclexta, Polivy |
| Servier Pharmaceuticals LLC | $61.04 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.71 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $54.05 | 2025 | Calquence |
| Ipsen Biopharmaceuticals, INC | $46.80 | 2025 | Onivyde |
| Sobi, INC | $46.76 | 2025 | |
| Adaptive Biotechnologies Corporation | $40.03 | 2025 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $35.00 | 2025 | Strensiq |
| Janssen Biotech, INC. | $31.57 | 2025 | Rybrevant |
| Exelixis INC. | $25.04 | 2025 | Cabometyx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $24.86 | 2025 | Ayvakit |
| Geron Corporation | $24.82 | 2025 | Rytelo |
| Daiichi Sankyo INC. | $24.09 | 2025 | Enhertu |
| Sumitomo Pharma America, INC. | $23.36 | 2025 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.73 | 2025 | |
| Agios Pharmaceuticals, INC. | $22.07 | 2025 | Pyrukynd |
| Abbvie INC. | $20.71 | 2025 | |
| Aveo Pharmaceuticals, INC. | $20.53 | 2025 | |
| Eisai INC. | $16.98 | 2025 | |
| Pharmaand Gmbh | $14.27 | 2025 | Rubraca |
| Tolmar, INC. | $14.27 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iraj Rueda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.